Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||24 Jun 2022||Lorem|
|LoA Update: Incyte’s advanced malignancies candidate plunges in regulatory chances after Phase I/II terminates||15 Dec 2021||William Newton|
|JAK inhibitors still have valuable uptake opportunities in moderate-to-severe atopic dermatitis despite threat of black box warning||23 Sep 2021||Reynald Castaneda|
|LoA Update: Incyte’s potential for its Phase II asset for kidney cancer to move to the next developmental stage plummets to 22%||22 Jul 2021||Humeza Ahmed|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer